NicOx enters Ph I with Lipitor competitor
France-based NicOx has initiated clinical development for NCX 6560, a novel, nitric oxide-donating compound which could become an improved investigational drug for serious cardiovascular diseases.
A first-in-man study will enroll both healthy male volunteers and those with abnormally-raised cholesterol and will compare NCX 6560 to placebo and Pfizer's Lipitor (atorvastatin), with a preliminary evaluation of activity, safety and tolerability.
The initiation of the study follows promising preclinical results, which suggest NCX 6560 could inhibit multiple steps in the development of atherosclerosis, a key dysfunction underlying cardiovascular disorders, according to NicOx.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze